AFFX Affymetrix, Inc.

Affymetrix Inc. (Nasdaq:AFFX) today announced that it has been named as one of the world�s top 50 most innovative companies by Fast Company magazine, a prominent monthly publication with a worldwide circulation in excess of 730,000 that focuses on new business practices and individuals who are reinventing business. Affymetrix was the only life sciences company to be recognized in the 2008 Fast 50: The World�s 50 Most Innovative Companies annual poll, published in the March 2008 issue of Fast Company. The company was commended for its work relating to the discovery of genetic variations and drug metabolism. Ranked 13th, Affymetrix sits alongside innovation giants and mainstream brands such as Google, Apple, Nike, Facebook, Nokia and Nintendo. To view the Affymetrix listing, please visit: http://www.fastcompany.com/multimedia/slideshows/content/ fast50_08.html?page=38 (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.) In preparing the annual poll, Fast Company�s editors and researchers spoke to numerous experts and conducted a detailed analysis of each company�s financial information and products. According to the publication, the featured companies are �pushing business to new places and taking chances beyond what is expected, proving beyond doubt that business is a force for change.� �We consulted dozens of our contributors around the world who took nominations from experts and business leaders in every industry,� said Tom Foster, editor of the 2008 Fast 50. �We didn�t look only at small companies or only at major conglomerates � we considered any company whose innovations in the past year have proven game-changing in their fields. That meant looking at everything from how they treat their employees to how they manage their supply chains to, of course, their most dazzling new products. In the end, a panel of Fast Company editors and writers voted on more than 300 finalists to come up with the ultimate list of 50. Affymetrix stood out not only because it�s part of a hot field with tremendous possibility, but also because so much of that possibility is already being realized.� �This recognition by Fast Company is a great achievement for Affymetrix and a direct reflection of our tremendous depth of talent,� said Kevin King, President of Affymetrix. �Looking to the future, we�re intensely committed to maintaining our leadership position with new innovations that will continue to accelerate genetic discoveries and transform the future of patient care and treatment. In fact, customers are now using our recently released DMET solution to better understand an individual�s response to different drugs like warfarin1, which will ultimately help improve the drug dosing dilemma and reduce the risks of adverse reactions.� About Affymetrix Affymetrix GeneChip� microarray technology is the industry-standard tool for analyzing complex genetic information. After inventing microarray technology in the late 1980s, Affymetrix scientists have been dedicated to developing innovative products that provide researchers with a more complete view of the genome. These products continue to accelerate genetic research and enable scientists to develop diagnostics and tailor treatments for individual patients by identifying and measuring the genetic information associated with complex diseases. Today, Affymetrix technology is used by the world�s top pharmaceutical, diagnostic and biotechnology companies, as well as leading academic, government and not-for-profit research institutes. More than 1,700 systems have been shipped around the world and more than 11,000 peer-reviewed papers have been published using the technology. Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Sacramento, Calif., Cleveland, Ohio, and Singapore. The company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit: www.affymetrix.com. Forward-looking Statements All statements in this press release that are not historical are �forward-looking statements� within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix� �expectations,� �beliefs,� �hopes,� �intentions,� �strategies� or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to: risks and uncertainties relating to Affymetrix� ranking in Fast Company�s �2008 Fast 50: The World�s 50 Most Innovative Companies,� discussed in this press release; risks of the company�s ability to achieve and sustain higher levels of revenue, higher gross margins and reduced operating expenses; uncertainties related to technological approaches, manufacturing and product development; personnel retention; uncertainties related to cost and pricing of Affymetrix products; dependence on collaborative partners; uncertainties related to sole-source suppliers; risks associated with past and future acquisitions; uncertainties relating to FDA and other regulatory approvals; competition; risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix� Form 10-K for the year ended December 31, 2006, and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix� expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. NOTE: Affymetrix, the Affymetrix logo and GeneChip� are registered trademarks owned or used by Affymetrix Inc. 1 http://investor.affymetrix.com/phoenix.zhtml?c=116408&p=irol-news Article&ID=1105493 (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)